| Madeline Zola Williams, | |
|
18035 Brookhurst St., Ste. 2100, Fountain Valley, CA 92708 | |
| (657) 241-9090 | |
| (714) 665-4603 |
| Full Name | Madeline Zola Williams |
|---|---|
| Gender | Female |
| Speciality | Midwife |
| Location | 18035 Brookhurst St., Ste. 2100, Fountain Valley, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467184408 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | CNM236251 (California) | Secondary |
| 176B00000X | Midwife | 236251 (California) | Primary |
| Entity Name | Memorialcare Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205167350 PECOS PAC ID: 8729277314 Enrollment ID: O20110113000219 |
News Archive
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for orphan drug designation for ALS-886, a novel therapy to reduce and prevent tissue damage, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Suspected opioid overdose patients treated with naloxone are safe for discharge from the emergency department after one hour.
Food safety experts from around the world will be at Queen's University Belfast this week (8-10 April) to highlight current and emerging threats to the integrity of the food chain.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Madeline Zola Williams, 18035 Brookhurst St., Ste. 2100, Fountain Valley, CA 92708 Ph: (657) 241-9090 | Madeline Zola Williams, 18035 Brookhurst St., Ste. 2100, Fountain Valley, CA 92708 Ph: (657) 241-9090 |
News Archive
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for orphan drug designation for ALS-886, a novel therapy to reduce and prevent tissue damage, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Suspected opioid overdose patients treated with naloxone are safe for discharge from the emergency department after one hour.
Food safety experts from around the world will be at Queen's University Belfast this week (8-10 April) to highlight current and emerging threats to the integrity of the food chain.
› Verified 8 days ago